2020
A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer.
Lu M, Walia G, Schulze K, Doral M, Maund S, Gaffey S, Cabili M, Bourla A, Green R, Santos E, Herbst R, Chiang A, Schwartzberg L. A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer. Journal Of Clinical Oncology 2020, 38: tps2087-tps2087. DOI: 10.1200/jco.2020.38.15_suppl.tps2087.Peer-Reviewed Original ResearchCell lung cancerLung cancerOverall survivalOutcome dataExtensive-stage small-cell lung cancerMetastatic non-small cell lung cancerNon-small cell lung cancerSmall cell lung cancerReal-world clinical outcomesGenomic profilingFirst tumor assessmentFlatiron Health networkTechnology-enabled abstractionLines of therapyMetastatic lung cancerEnd of treatmentWithdrawal of consentClinical data pointsEnd of studyTumor DNA ProfilingAnti-neoplastic treatmentCase report formsTumor tissue samplesBlood genomic profilingElectronic health records
2018
Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials
O’Connor J, Fessele KL, Steiner J, Seidl-Rathkopf K, Carson KR, Nussbaum NC, Yin ES, Adelson KB, Presley CJ, Chiang AC, Ross JS, Abernethy AP, Gross CP. Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials. JAMA Oncology 2018, 4: e180798-e180798. PMID: 29800974, PMCID: PMC6143052, DOI: 10.1001/jamaoncol.2018.0798.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, Monoclonal, HumanizedCarcinoma, Non-Small-Cell LungCarcinoma, Renal CellClinical Trials as TopicFemaleFollow-Up StudiesHumansKidney NeoplasmsLung NeoplasmsMaleMiddle AgedNivolumabPractice Patterns, Physicians'PrognosisProgrammed Cell Death 1 ReceptorRetrospective StudiesConceptsNon-small cell lung cancerPivotal clinical trialsRenal cell carcinomaCell death 1 proteinEligible patientsImmune checkpoint inhibitorsDeath 1 proteinClinical trialsClinical practiceFDA approvalAgent treatmentCheckpoint inhibitorsAnti-PD-1 agentsFlatiron Health networkRetrospective cohort studyAge of patientsCell lung cancerClinical trial participantsCohort studyPatient ageYounger patientsMore patientsSuch patientsTrial evidenceCell carcinoma
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply